AccuStem Sciences, Inc. Appoints New Executive Leadership Team
04 Mars 2022 - 1:00PM
AccuStem Sciences, Inc. (OTC PINK: ACUT), a life sciences company
dedicated to improving outcomes for patients with cancer, today
announced the formation of its executive leadership team as the
first major step toward commercializing new products in the
oncology space.
Wendy Blosser, a commercial executive with extensive leadership
experience at diagnostic companies in the oncology sector, has been
named Chief Executive Officer and a member of the board of
directors for AccuStem. Wendy most recently served as the Chief
Commercial Officer for Agendia, a leading breast oncology company,
where she led the organization to its highest sales volume and
revenue since its inception. Prior to that, Wendy served as the
Chief Commercial Officer at Biodesix where she oversaw the launch
and rapid growth of its blood-based genomic testing, GeneStrat.
“With the recent publication of our TransATAC analysis, I am
pleased with the StemPrintER results to date, and believe the
science behind the test will be applicable across different tumor
types,” said Wendy Blosser. “My vision is to build a company that
offers a multitude of products- whether it’s an esoteric diagnostic
test or a novel therapeutic- that improve outcomes for cancer
patients.”
Also joining the leadership team are Jeff Fensterer, as Chief
Operations Officer, and Joe Flanagan, as Chief Business Officer.
Jeff brings an exceptional track record in long term strategic
planning that is enhanced by his experience in a broad spectrum of
roles including marketing, sales, market access, lab operations and
product development. Joe brings 25 years of sales excellence as a
strategic expert in the commercial development and successful
launch of new and on-market products. Both executives have led
companies at various stages, from early start up to Fortune 500, to
consistent and rapid growth in sales volume and revenue, most
recently with Agendia.
With the formation of the management team, AccuStem, a spinoff
from Tiziana Life Sciences Ltd., (NASDAQ: TLSA) will be
building its corporate headquarters in Phoenix, Arizona. The
company is currently listed on the OTC PINK (ACUT) and plans to
file an application to list its common stock on the Nasdaq Capital
Market.
“We are pleased to have such an accomplished leadership team
taking the reins at AccuStem,” said Gabriele Cerrone, Chairman.
“Given the breadth of their commercial experience in building
companies such as Agendia, Biodesix and Cytyc Corporation (now
Hologic), we believe this management team has the right skills to
develop strong product and clinical research pipelines, and
ultimately successfully commercialize new technologies at
AccuStem.”
About AccuStem
AccuStem is a life sciences company dedicated to optimizing
outcomes for all patients with cancer across the globe. The company
takes a holistic view of its role in oncology- to empower patients
and their care team with critical answers and tools and drive
innovation in healthcare.
Forward-Looking Statements
This press release contains “forward-looking statements”
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements. AccuStem Sciences, Inc.
assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the
date of this release.
Media Contact:Jeff FenstererPhone:
415-640-6010Email: jfensterer@accustem.com
Investor Contact:Wendy BlosserEmail:
investors@accustem.com
Tiziana Life Sciences (NASDAQ:TLSA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024